Bacteriophage therapy - cooked goose or Phoenix rising?

M. Mattey, J. Spencer

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Recent animal and human trials of bacteriophage therapy have demonstrated its potential to alleviate bacterial diseases, both in internal and in external applications. The regulatory requirements are becoming clearer as more examples are presented. A core of GLP (Good Laboratory Practice) studies will be needed to validate safety and clinical trials to validate efficacy. GMP (Good Manufacturing Practice) production requirements and quality issues will mean that comparable costs to the production of conventional antibiotics should be anticipated. The definition of the 'active substance' will be central to the success of bacteriophage therapy to ensure that the variety and evolutionary potential of bacteriophages are exploited.
LanguageEnglish
Pages608-612
Number of pages4
JournalCurrent Opinion in Biotechnology
Volume19
Issue number6
DOIs
Publication statusPublished - Dec 2008

Fingerprint

Geese
Bacteriophages
Clinical Trials
Antibiotics
Anti-Bacterial Agents
Safety
Costs and Cost Analysis
Animals
Phage Therapy
Costs

Keywords

  • bacteriophage therapy
  • animal
  • human trials

Cite this

Mattey, M. ; Spencer, J. / Bacteriophage therapy - cooked goose or Phoenix rising?. In: Current Opinion in Biotechnology. 2008 ; Vol. 19, No. 6. pp. 608-612.
@article{56947e12872d4757889e36e3372be762,
title = "Bacteriophage therapy - cooked goose or Phoenix rising?",
abstract = "Recent animal and human trials of bacteriophage therapy have demonstrated its potential to alleviate bacterial diseases, both in internal and in external applications. The regulatory requirements are becoming clearer as more examples are presented. A core of GLP (Good Laboratory Practice) studies will be needed to validate safety and clinical trials to validate efficacy. GMP (Good Manufacturing Practice) production requirements and quality issues will mean that comparable costs to the production of conventional antibiotics should be anticipated. The definition of the 'active substance' will be central to the success of bacteriophage therapy to ensure that the variety and evolutionary potential of bacteriophages are exploited.",
keywords = "bacteriophage therapy, animal, human trials",
author = "M. Mattey and J. Spencer",
year = "2008",
month = "12",
doi = "10.1016/j.copbio.2008.09.001",
language = "English",
volume = "19",
pages = "608--612",
journal = "Current Opinion in Biotechnology",
issn = "0958-1669",
number = "6",

}

Bacteriophage therapy - cooked goose or Phoenix rising? / Mattey, M.; Spencer, J.

In: Current Opinion in Biotechnology, Vol. 19, No. 6, 12.2008, p. 608-612.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Bacteriophage therapy - cooked goose or Phoenix rising?

AU - Mattey, M.

AU - Spencer, J.

PY - 2008/12

Y1 - 2008/12

N2 - Recent animal and human trials of bacteriophage therapy have demonstrated its potential to alleviate bacterial diseases, both in internal and in external applications. The regulatory requirements are becoming clearer as more examples are presented. A core of GLP (Good Laboratory Practice) studies will be needed to validate safety and clinical trials to validate efficacy. GMP (Good Manufacturing Practice) production requirements and quality issues will mean that comparable costs to the production of conventional antibiotics should be anticipated. The definition of the 'active substance' will be central to the success of bacteriophage therapy to ensure that the variety and evolutionary potential of bacteriophages are exploited.

AB - Recent animal and human trials of bacteriophage therapy have demonstrated its potential to alleviate bacterial diseases, both in internal and in external applications. The regulatory requirements are becoming clearer as more examples are presented. A core of GLP (Good Laboratory Practice) studies will be needed to validate safety and clinical trials to validate efficacy. GMP (Good Manufacturing Practice) production requirements and quality issues will mean that comparable costs to the production of conventional antibiotics should be anticipated. The definition of the 'active substance' will be central to the success of bacteriophage therapy to ensure that the variety and evolutionary potential of bacteriophages are exploited.

KW - bacteriophage therapy

KW - animal

KW - human trials

U2 - 10.1016/j.copbio.2008.09.001

DO - 10.1016/j.copbio.2008.09.001

M3 - Article

VL - 19

SP - 608

EP - 612

JO - Current Opinion in Biotechnology

T2 - Current Opinion in Biotechnology

JF - Current Opinion in Biotechnology

SN - 0958-1669

IS - 6

ER -